Solifenacin

Summary

Solifenacin (CHEMBL1734) is an approved small molecule (ATC G04BD08) targeting CHRM1, CHRM2, and CHRM3; indicated across 5 conditions including overactive bladder and benign prostatic hyperplasia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BD08
• Targets: 5 (CHRM1, CHRM2, CHRM3…)
• Indications: 5 conditions
• Clinical trials: 125
• Chemistry: 362.5 Da · C23H26N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1734
Name	Solifenacin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	154059
ATC	G04BD08
Molecular formula	C23H26N2O2
Molecular weight	362.5
InChIKey	FBOUYBDGKBSUES-VXKWHMMOSA-N

SMILES: C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

IUPAC name: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate

Also known as: NSC-759144, Solifenacin, Solifenacina, Solifenacine, Vesicare, SID50113280, SID144206192, solifenacin, SOLIFENACIN, SOLIFENACIN SUCCINATE

Parent form; salt/anhydrous children: CHEMBL1200803

Patent coverage: 125 distinct patent families (296 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CHRM1	M1 receptor	Antagonist	7.6	0.2%	P11229
CHRM2	M2 receptor	Antagonist	7.1	0%	P08172
CHRM3	M3 receptor	Antagonist	8	0%	P20309
CHRM4	M4 receptor	Antagonist	6.8	1.6%	P08173
CHRM5	M5 receptor	Antagonist	7.2	0%	P08912

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Voltage-dependent L-type calcium channel subunit alpha-1C, A-type voltage-gated potassium channel KCND3, Sodium channel protein type 5 subunit alpha, Muscarinic acetylcholine receptor M5, Voltage-gated L-type calcium channel, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Voltage-gated potassium channel, IKs; KCNQ1(Kv7.1)/KCNE1(MinK), Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 16 potent at pChembl ≥ 5 of 18 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08482	8	Ki	10	nM	CHEMBL_ACT_1613280
P08483	8	Ki	10	nM	CHEMBL_ACT_1613282
CHRM3	7.88	Ki	13.18	nM	CHEMBL_ACT_18279150
CHRM3	7.62	IC50	24	nM	CHEMBL_ACT_23214872
CHRM3	7.62	EC50	24	nM	CHEMBL_ACT_25015657
CHRM5	7.36	Ki	43.65	nM	CHEMBL_ACT_18279180
CHRM1	7.29	Ki	51.29	nM	CHEMBL_ACT_18279110
P10980	6.92	Ki	120	nM	CHEMBL_ACT_1613281
CHRM2	6.92	Ki	120.2	nM	CHEMBL_ACT_18279135
CHRM4	6.89	Ki	128.8	nM	CHEMBL_ACT_18279165
KCNH2	6.6	IC50	251.2	nM	CHEMBL_ACT_15258098
KCNH2	6.57	IC50	270	nM	CHEMBL_ACT_25015630
KCNH2	5.8	IC50	1585	nM	CHEMBL_ACT_15258038
CACNA1F	5.37	IC50	4300	nM	CHEMBL_ACT_15373358
CACNA1C	5.2	IC50	6310	nM	CHEMBL_ACT_15258132
SCN5A	5.2	IC50	6310	nM	CHEMBL_ACT_15258192

Target pathways

Aggregated over 5 target gene(s): CHRM1, CHRM2, CHRM3, CHRM4, CHRM5.

Top Reactome pathways

17 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Signaling by GPCR	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Class A/1 (Rhodopsin-like receptors)	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Amine ligand-binding receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR downstream signalling	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Muscarinic acetylcholine receptors	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GPCR ligand binding	5	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
G alpha (q) signalling events	3	CHRM1, CHRM3, CHRM5
G alpha (i) signalling events	2	CHRM2, CHRM4
Metabolism	1	CHRM3
Integration of energy metabolism	1	CHRM3
Membrane Trafficking	1	CHRM2
Acetylcholine regulates insulin secretion	1	CHRM3
Regulation of insulin secretion	1	CHRM3
Vesicle-mediated transport	1	CHRM2
Cargo recognition for clathrin-mediated endocytosis	1	CHRM2
Clathrin-mediated endocytosis	1	CHRM2

Dominant GO biological processes

GO term	Targets
signal transduction	5
G protein-coupled receptor signaling pathway	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	5
G protein-coupled acetylcholine receptor signaling pathway	5
chemical synaptic transmission	5
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	3
nervous system development	3
acetylcholine receptor signaling pathway	3
regulation of locomotion	2
saliva secretion	2
regulation of smooth muscle contraction	2
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuromuscular synaptic transmission	1
positive regulation of monoatomic ion transport	1

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
overactive bladder	3	MONDO:0006624	EFO:1000781
benign prostatic hyperplasia	3	MONDO:0010811	EFO:0000284

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 125.

Phase distribution

Phase	Trials
PHASE4	42
Not specified	34
PHASE3	26
PHASE1	10
PHASE2	9
PHASE1/PHASE2	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06465576	PHASE4	RECRUITING	Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
NCT07416968	PHASE4	RECRUITING	Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
NCT07473310	PHASE4	RECRUITING	Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
NCT00333112	PHASE4	COMPLETED	A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
NCT00337558	PHASE4	COMPLETED	A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
NCT00431041	PHASE4	COMPLETED	Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
NCT00573508	PHASE4	COMPLETED	Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
NCT00629642	PHASE4	COMPLETED	Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
NCT00699049	PHASE4	COMPLETED	A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder
NCT00759577	PHASE4	TERMINATED	Feasibility of At-home Titration of Solifenacin
NCT00771394	PHASE4	COMPLETED	Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
NCT00773552	PHASE4	WITHDRAWN	Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
NCT00884104	PHASE4	COMPLETED	A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks
NCT00909428	PHASE4	COMPLETED	Validation of a Real-time Urodynamic Measure of Urinary Urgency
NCT00979472	PHASE4	COMPLETED	Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency
NCT01092624	PHASE4	TERMINATED	Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse
NCT01093534	PHASE4	COMPLETED	Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
NCT01126424	PHASE4	COMPLETED	A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person’s Mental Ability
NCT01314781	PHASE4	COMPLETED	Therapy of the Overactive Bladder Syndrome
NCT01318837	PHASE4	COMPLETED	A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment
NCT01371994	PHASE4	COMPLETED	A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
NCT01423838	PHASE4	UNKNOWN	Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
NCT01457573	PHASE4	COMPLETED	Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
NCT01505439	PHASE4	COMPLETED	A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence
NCT01533597	PHASE4	COMPLETED	The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
NCT01559389	PHASE4	COMPLETED	Incontinence & Intimate Partners: Assessing the Contribution of Treatment
NCT01745094	PHASE4	COMPLETED	A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NCT01747577	PHASE4	COMPLETED	Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
NCT01777217	PHASE4	TERMINATED	VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
NCT01833663	PHASE4	COMPLETED	Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women
NCT01880619	PHASE4	COMPLETED	Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms
NCT02094703	PHASE4	UNKNOWN	The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females
NCT02294396	PHASE4	COMPLETED	Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
NCT02540707	PHASE4	COMPLETED	Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
NCT02667470	PHASE4	COMPLETED	Reproducibility Study of OABSS and Its Response to Treatment
NCT02715024	PHASE4	COMPLETED	Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms
NCT03468465	PHASE4	UNKNOWN	Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome
NCT03558919	PHASE4	COMPLETED	Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder
NCT04090190	PHASE4	COMPLETED	Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
NCT04909255	PHASE4	UNKNOWN	Beta-3 Agonist and Anti-muscarinic Agent for Sjogren’s Syndrome With Overactive Bladder
NCT05494567	PHASE4	UNKNOWN	Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB
NCT07114848	PHASE4	COMPLETED	Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ.
NCT06551246	PHASE3	RECRUITING	Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
NCT06803030	PHASE3	RECRUITING	Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms
NCT07114640	PHASE3	NOT_YET_RECRUITING	The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial
NCT07429734	PHASE3	NOT_YET_RECRUITING	Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women
NCT00189800	PHASE3	COMPLETED	A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
NCT00368706	PHASE3	COMPLETED	A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
NCT00454740	PHASE3	COMPLETED	Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
NCT00463541	PHASE3	COMPLETED	Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
NCT00801944	PHASE3	COMPLETED	Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
NCT00802373	PHASE3	COMPLETED	Solifenacin Succinate Versus Tolterodine 4mg Once Daily
NCT00821184	PHASE3	TERMINATED	Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
NCT01018511	PHASE3	COMPLETED	Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
NCT01166438	PHASE3	COMPLETED	Anticholinergic vs. Botox Comparison Study
NCT01486706	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of Gabapentin in Treating Overactive Bladder
NCT01565694	PHASE3	COMPLETED	A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
NCT01638000	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
NCT01767519	PHASE3	COMPLETED	A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
NCT01908829	PHASE3	COMPLETED	A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
NCT01972841	PHASE3	COMPLETED	This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
NCT01981954	PHASE3	COMPLETED	A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
NCT02045862	PHASE3	COMPLETED	A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
NCT02827578	PHASE3	UNKNOWN	Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
NCT03149809	PHASE3	COMPLETED	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
NCT04023253	PHASE3	UNKNOWN	Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
NCT04325880	PHASE3	UNKNOWN	Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
NCT05282069	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
NCT05490082	PHASE3	UNKNOWN	Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation
NCT01530373	PHASE2	RECRUITING	Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
NCT00507455	PHASE2	COMPLETED	Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
NCT00510406	PHASE2	COMPLETED	A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
NCT01340027	PHASE2	COMPLETED	A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
NCT01642277	PHASE2	COMPLETED	Bacterial Genomic Sequencing in Overactive Bladder
NCT01737411	PHASE1/PHASE2	UNKNOWN	Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women
NCT01737918	PHASE1/PHASE2	UNKNOWN	Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa
NCT02549196	PHASE2	COMPLETED	A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer’s Type
NCT03106623	PHASE2	COMPLETED	Study of ONO-8577 in Patients With Overactive Bladder
NCT03566134	PHASE2	COMPLETED	A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
NCT03632772	PHASE2	UNKNOWN	Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP
NCT05240456	PHASE1/PHASE2	UNKNOWN	Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children
NCT00832650	PHASE1	TERMINATED	Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit
NCT01297192	PHASE1	COMPLETED	A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
NCT01406158	PHASE1	COMPLETED	A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation
NCT01953887	PHASE1	COMPLETED	A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin
NCT02010944	PHASE1	COMPLETED	A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels
NCT02127034	PHASE1	COMPLETED	Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
NCT02169713	PHASE1	COMPLETED	Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
NCT02180997	PHASE1	COMPLETED	Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
NCT02494349	PHASE1	COMPLETED	The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.
NCT02634489	PHASE1	COMPLETED	EC905 Pharmacokinetic Profile Study
NCT05798403	Not specified	RECRUITING	Efficacy of Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder
NCT06201013	Not specified	RECRUITING	Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
NCT07305298	Not specified	NOT_YET_RECRUITING	Mirabegron in Patients With Age-Related Macular Degeneration
NCT00441428	Not specified	COMPLETED	Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity
NCT00581061	Not specified	TERMINATED	Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy
NCT00852696	Not specified	TERMINATED	Over Active Bladder Patients Having Sling Surgery
NCT00985387	Not specified	COMPLETED	Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
NCT01028014	Not specified	COMPLETED	Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
NCT01122563	Not specified	COMPLETED	A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

576 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOZAPINE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
Mavorixafor	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OLANZAPINE	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ACETYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMIODARONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
AMOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZTROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BETHANECHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBACHOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CARBAMOYLCHOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CINNARIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLEMASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLIDINIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYCLIZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DARIFENACIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DESLORATADINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DEXCHLORPHENIRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DICYCLOMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIPHENIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DOXEPIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
EBASTINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
GLYCOPYRRONIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HALOPERIDOL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HOMATROPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
HYDROXYCHLOROQUINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
IMIPRAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
IPRATROPIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
KETOTIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
LOXAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MAPROTILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MEPAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
METHSCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
METHSCOPOLAMINE BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
MIANSERIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ORPHENADRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
OXYBUTYNIN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PAROXETINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PERHEXILINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PILOCARPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PIRENZEPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PROMETHAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUETIAPINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
QUINACRINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
RISPERIDONE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SCOPOLAMINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SERTRALINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SULOCTIDIL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TAMOXIFEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TERCONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
THIORIDAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TIOTROPIUM BROMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TOLTERODINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TRIHEXYPHENIDYL	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TROPICAMIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TROSPIUM CHLORIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
XANOMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
DIMETHINDENE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ENCLOMIPHENE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
ABAPERIDONE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
APROFENE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BENZETHONIUM CHLORIDE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
FLUNARIZINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
PF-03635659	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
SABCOMELINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
TALSACLIDINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5
BETAMETHASONE PHOSPHORIC ACID	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM4, CHRM5
BIPERIDEN	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM4, CHRM5
CEVIMELINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
ECONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
FLUOXETINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM5
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
MICONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3, CHRM4
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM4, CHRM5
SULCONAZOLE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM4, CHRM5
BLARCAMESINE	ChEMBL	Phase 3	CHRM1, CHRM2, CHRM3, CHRM4
METHYLBENACTYZIUM BROMIDE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
OTENZEPAD	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
ZOTEPINE	ChEMBL	Phase 2	CHRM1, CHRM2, CHRM3, CHRM4
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
chenodiol	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
LINAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	CHRM1, CHRM2, CHRM3
ACETYLCHOLINE CHLORIDE	ChEMBL	Phase 4 (approved)	CHRM1, CHRM3, CHRM5
AMBENONIUM	ChEMBL	Phase 4 (approved)	CHRM1, CHRM2, CHRM3